Aspiriant LLC Sells 327 Shares of Bristol-Myers Squibb Co (NYSE:BMY)

Aspiriant LLC reduced its stake in Bristol-Myers Squibb Co (NYSE:BMY) by 5.1% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 6,103 shares of the biopharmaceutical company’s stock after selling 327 shares during the period. Aspiriant LLC’s holdings in Bristol-Myers Squibb were worth $312,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of BMY. First Trust Advisors LP lifted its stake in Bristol-Myers Squibb by 20.4% during the third quarter. First Trust Advisors LP now owns 1,978,449 shares of the biopharmaceutical company’s stock worth $100,327,000 after purchasing an additional 335,667 shares during the last quarter. Kahn Brothers Group Inc. DE lifted its stake in Bristol-Myers Squibb by 5.2% during the third quarter. Kahn Brothers Group Inc. DE now owns 1,071,235 shares of the biopharmaceutical company’s stock worth $54,322,000 after purchasing an additional 52,955 shares during the last quarter. Daiwa Securities Group Inc. lifted its stake in Bristol-Myers Squibb by 8.3% during the third quarter. Daiwa Securities Group Inc. now owns 71,800 shares of the biopharmaceutical company’s stock worth $3,641,000 after purchasing an additional 5,531 shares during the last quarter. Donaldson Capital Management LLC lifted its stake in Bristol-Myers Squibb by 501.9% during the third quarter. Donaldson Capital Management LLC now owns 50,975 shares of the biopharmaceutical company’s stock worth $2,585,000 after purchasing an additional 42,506 shares during the last quarter. Finally, First National Bank of Omaha lifted its stake in Bristol-Myers Squibb by 10.7% during the third quarter. First National Bank of Omaha now owns 16,214 shares of the biopharmaceutical company’s stock worth $822,000 after purchasing an additional 1,565 shares during the last quarter. Institutional investors and hedge funds own 80.40% of the company’s stock.

Several equities research analysts have weighed in on the company. Peel Hunt restated a “buy” rating on shares of Bristol-Myers Squibb in a research note on Tuesday, October 29th. Atlantic Securities upgraded Bristol-Myers Squibb from a “neutral” rating to an “overweight” rating and set a $63.00 target price for the company in a research note on Wednesday, August 14th. UBS Group upped their target price on Bristol-Myers Squibb from $51.00 to $53.00 and gave the stock a “neutral” rating in a research note on Wednesday, October 23rd. Bank of America assumed coverage on Bristol-Myers Squibb in a research note on Wednesday, October 16th. They set a “buy” rating and a $60.00 target price for the company. Finally, JPMorgan Chase & Co. set a $62.00 target price on Bristol-Myers Squibb and gave the stock a “buy” rating in a research note on Friday, September 13th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and eleven have given a buy rating to the company’s stock. Bristol-Myers Squibb currently has an average rating of “Buy” and an average price target of $56.64.

In related news, insider Louis S. Schmukler sold 25,000 shares of the stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $56.56, for a total value of $1,414,000.00. Following the completion of the sale, the insider now directly owns 31,963 shares in the company, valued at $1,807,827.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP John E. Elicker sold 15,000 shares of the stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $56.66, for a total value of $849,900.00. Following the completion of the sale, the senior vice president now owns 74,471 shares of the company’s stock, valued at $4,219,526.86. The disclosure for this sale can be found here. 0.13% of the stock is currently owned by corporate insiders.

Shares of NYSE:BMY opened at $58.02 on Friday. The company has a fifty day moving average of $52.90 and a 200-day moving average of $48.19. The company has a market capitalization of $91.88 billion, a PE ratio of 14.58, a price-to-earnings-growth ratio of 1.31 and a beta of 0.71. The company has a debt-to-equity ratio of 1.37, a quick ratio of 3.72 and a current ratio of 3.83. Bristol-Myers Squibb Co has a 52-week low of $42.48 and a 52-week high of $58.46.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported $1.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.06 by $0.11. The company had revenue of $6.01 billion during the quarter, compared to the consensus estimate of $5.89 billion. Bristol-Myers Squibb had a net margin of 23.53% and a return on equity of 45.49%. The company’s revenue for the quarter was up 5.6% compared to the same quarter last year. During the same period in the prior year, the business earned $1.09 earnings per share. On average, equities analysts forecast that Bristol-Myers Squibb Co will post 4.33 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Friday, November 1st. Stockholders of record on Friday, October 4th were issued a dividend of $0.41 per share. The ex-dividend date of this dividend was Thursday, October 3rd. This represents a $1.64 annualized dividend and a dividend yield of 2.83%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 41.21%.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

Recommended Story: What is meant by buying and selling pressure?

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.